The Cyano Is Bonded Directly To A Benzene Ring Patents (Class 514/522)
  • Patent number: 10300037
    Abstract: This invention is directed to substituted acylanilide compounds and uses thereof in treating muscular dystrophies such as Duchenne muscular dystrophy and Becker muscular dystrophy and in improving or preserving lung function and cardiac function in a subject suffering from Duchenne muscular dystrophy.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 28, 2019
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Thamarai Ponnusamy, Ramesh Narayanan
  • Patent number: 9970060
    Abstract: Disclosed are methods of quantifying microflora in vaginal samples. Quantitative assessment of vaginal microflora by real-time PCR to create a profiling of Lactobacillus species, Gardnerella vaginalis, Atopobium vaginae, Megasphaera Type 1 and Type 2 and BVAB2 permits evaluation of bacterial vaginosis. Kits containing reagents for quantitative assessment of microflora are also disclosed.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: May 15, 2018
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Sergey Balashov, Martin E. Adelson, Charronne Davis
  • Patent number: 9938230
    Abstract: Esters or salts of 2-hydroxy-4-propyleyclohepta-2,4,6-trienone, and applications thereof in preparation of animal antibacterial agents and growth promoters used in feed. The esters or salts of 2-hydroxy-4-propylcyclohepta-2,4,6-trienone has a structural formula as shown in formula 1 or 2: in formula 1, R1 represents heptadecyl; and in formula 2, L is sodium, potassium, calcium, magnesium, zinc, copper or manganese. The esters or salts of 2-hydroxy-4-propyleyclohepta-2,4,6-trienone, as shown in formula 1 or 2, have high stability and safety, and good antibacterial and growth promotion effects, which make them preferable to be used as animal antibacterial agents and growth promoters in feed, and have a very good application prospect in the cultivation industry.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: April 10, 2018
    Assignee: GUANGZHOU INSIGHTER BIOTECHNOLOGY CO., LTD.
    Inventors: Xianfeng Peng, Zonghua Qin, Fang Li, Jijun Huang, Xiaolan Ye, Zaolong Li
  • Patent number: 9884038
    Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: February 6, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Duane D. Miller, Ramesh Narayanan, Thamarai Ponnusamy
  • Patent number: 9637793
    Abstract: The present invention provides microRNAs for assessing the status of pancreatic cancer in a subject, and provides methods, kits, and biochips for detecting said microRNAs.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: May 2, 2017
    Assignee: Micromedmark Biotech Co., Ltd.
    Inventors: Chenyu Zhang, Rui Liu, Cheng Wang, Yi Bai, Chunni Zhang, Ke Zeng
  • Patent number: 9611513
    Abstract: The invention relates to methods for detecting allogeneic therapeutic cells (such as human umbilical cord tissue-derived cells (hUTC)) in blood. The methods includes the steps of identifying one or more one or more markers positive for allogeneic therapeutic cells (e.g. hUTC) and one or more markers positive for human peripheral blood mononuclear cells (PBMC); providing a blood sample from a patient that has been treated with allogeneic therapeutic cells (e.g. hUTC), analyzing the sample using an assay method to detect one or more markers positive for PBMC and one or more markers positive for allogeneic therapeutic cells (e.g. hUTC); and distinguishing between the PBMC and one or more markers positive for allogeneic therapeutic cells (e.g. hUTC). In one embodiment, the cells are hUTC and the markers positive of hUTC include CD10 and/or CD13 and the one or more markers positive for PBMC includes CD45.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: April 4, 2017
    Assignee: DePuy Synthes Products, Inc.
    Inventors: Haimanti Dorai, Reyna L. Favis, Xiang Yao, Yu Sun, Anthony J. Kihm, Stefanie Rassnick
  • Patent number: 9475749
    Abstract: This invention is directed to novel compounds isolated or derived from Alpiniae oxyphyllae fructus, chemically synthesized novel compounds, methods of preparing the novel compounds and uses thereof as neuroprotectants or drugs for treating neurodegenerative diseases such as Parkinson's disease.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 25, 2016
    Assignee: University of Macau
    Inventors: Ming Yuen Lee, Zaijun Zhang, Guohui Li
  • Patent number: 9150501
    Abstract: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: October 6, 2015
    Assignee: GTx, Inc.
    Inventors: James T. Dalton, Thomas G. Bird, Tai Ahn, David A. Dickason, Seoung-Soo Hong
  • Patent number: 9119832
    Abstract: The present technology generally is directed to methods for treating mild brain injury and other neurological disorders in a subject. The methods can include administering to the subject an effective amount of a compound comprising ghrelin. The present technology is also generally directed to methods for treating mild brain injury and other neurological disorders in a subject, for example, by administering to the subject an effective amount of a compound comprising ghrelin modified to include octanoic acid or by limiting the carbon 14 content.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: September 1, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Vishal Bansal
  • Publication number: 20150132408
    Abstract: The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.
    Type: Application
    Filed: June 20, 2013
    Publication date: May 14, 2015
    Inventors: Robert H. Weiss, Bruce D. Hammock, Hiromi Inoue, Sung Hee Hwang
  • Patent number: 9023869
    Abstract: Substituted phenylcarbamoyl alkylamino arenes; substituted phenylthiocarbamyl alkylamino arenes; substituted phenylcarbamoyl alkylamino heteroarenes; substituted phenylthiocarbamyl alkylamino heteroarenes; N-substituted aryl, N?-substituted aryl urea compounds; N-substituted aryl, N?-substituted heteroaryl urea compounds; N-substituted aryl, N?-substituted aryl thiourea compounds and N-substituted aryl, N?-substituted heteroaryl thiourea compounds are provided and may find use as androgen receptor modulators. The compounds may find particular use in treating prostate cancer, including castration-resistant prostate cancer and/or hormone-sensitive prostate cancer.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: May 5, 2015
    Assignee: Medivation Technologies, Inc.
    Inventors: Sarvajit Chakravarty, Rajendra Parasmal Jain
  • Patent number: 8975292
    Abstract: The present invention relates to a method for controlling arthropods comprising the application of an aqueous gel which contains an insecticide, an attractant and a thickener, wherein the aqueous gel is applied in the form of spots on fruit trees. The invention further relates to an aqueous gel comprising an insecticide, an attractant, a thickener, a humectant and a feeding stimulant. The invention also relates to a concentrated gel for preparing the aqueous gel.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: March 10, 2015
    Assignee: BASF SE
    Inventors: Claude Taranta, Tatjana Levy, Ouidad Benlahmar, Marc Nolte, Thomas Kröhl, Christoph Randt, Thomas Bork, Wolfgang Meier, Clark D. Klein, Tiffany Hennessey
  • Publication number: 20140350019
    Abstract: The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 27, 2014
    Applicant: FOVEA PHARMACEUTICALS
    Inventors: John Feutrill, Caroline Leriche, David Middlemiss
  • Publication number: 20140350102
    Abstract: This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
    Type: Application
    Filed: June 2, 2014
    Publication date: November 27, 2014
    Applicant: GTx, Inc.
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
  • Patent number: 8859590
    Abstract: Inhibitors of BACE1 and compositions containing them are described. Use of the inhibitors and compositions containing them to treat Alzheimer's disease are described.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: October 14, 2014
    Assignee: Purdue Research Foundation
    Inventor: Arun K. Ghosh
  • Patent number: 8853266
    Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating a variety of diseases or conditions in a subject, including, inter-alia, a diabetes disease, and/or disorder such as cardiovascular disease, atherosclerosis, cerebrovascular conditions, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: October 7, 2014
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller
  • Patent number: 8846756
    Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: September 30, 2014
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller
  • Publication number: 20140271955
    Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicants: The Scripps Research Institute, The California Institute for Biomedical Research
    Inventors: Peter G. SCHULTZ, Arnab K. CHATTERJEE, Shoutian ZHU, Joshua PAYETTE, Hongchul YOON, Baiyuan YANG
  • Publication number: 20140274692
    Abstract: A compound of formula (I) wherein R1 to R4 are, for example, each hydrogen, R5 is, for example, a substituted phenol; R6 is, for example, hydrogen; R7 is, for example, hydrogen, cyano, hydroxyl, formyl, C1-C4-alkyl, C1-C4-alkoxy, C2-C4-alkenyl, or C2-C4-alkynyl; and A1 to A5 is, for example, A1 is N or C—X, A3 is C—X, and A2, A4 and A5 are C—H, where X, is, for example, halogen; and its use as a pesticidal agent.
    Type: Application
    Filed: October 31, 2012
    Publication date: September 18, 2014
    Applicant: Syngenta Participations AG
    Inventors: Olivier Loiseleur, Thomas Pitterna, Anthony Cornelius O'Sullivan, Torsten Luksch, Anna Kickova
  • Publication number: 20140275037
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
    Type: Application
    Filed: December 19, 2013
    Publication date: September 18, 2014
    Applicant: Siga Technologies, Inc.
    Inventors: Yijun Deng, Theodore J. Nitz, Thomas R. Bailey, Yanming Zhang, Sylvie Laquerre
  • Patent number: 8835376
    Abstract: A process for making particles for delivery of drug nanoparticles is disclosed herein. The process comprises the steps of (a) forming a suspension of drug nanoparticles by mixing a precipitant solution with an anti-solvent solution under micro-mixing environment, where the formed nanoparticles have a narrow particle size distribution; (b) providing an excipient to at least one of the precipitant solution, the anti-solvent solution and the suspension of drug nanoparticles, the excipient being selected to maintain said drug nanoparticles in a dispersed state when in liquid form; and (c) drying the suspension of drug nanoparticles containing the excipient therein to remove solvent therefrom, wherein removal of the solvent causes the excipient to solidify and thereby form micro-sized matrix particles, each micro-sized particle being comprised of drug nanoparticles dispersed in a solid matrix of the excipient.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: September 16, 2014
    Assignee: Nanomaterials Technology Pte Ltd
    Inventors: Zhigang Shen, Jimmy Sung Lai Yun, Jun Hu, Nital Arvind Jugade, Jiyao Zhang, Wenhao Chen, Zhe Wang, Lingyan Gao, William Glover, Jian Feng Chen
  • Publication number: 20140221479
    Abstract: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.
    Type: Application
    Filed: January 30, 2014
    Publication date: August 7, 2014
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Duane D. Miller, Jeffrey D. Kearbey
  • Publication number: 20140213598
    Abstract: Disclosed is a substituted cyanoaniline compound or a salt thereof, wherein the compound has a structure represented by General Formula I. The compound of General Formula I has broad-spectrum fungicidal activity in the field of agriculture and effectively prevents against a variety of pathogens such as cucumber downy mildew, wheat powdery mildew, maize rust disease, rice blast and cucumber gray mold. In particular, even at a low dose, the compound effectively prevents and treats rice blast, cucumber gray mold, maize rust disease and cucumber downy mildew. Moreover, the raw materials for preparing the compounds are widely available and the synthesis method therefor is simple and convenient.
    Type: Application
    Filed: June 15, 2012
    Publication date: July 31, 2014
    Applicants: SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD., SINOCHEM CORPORATION
    Inventors: Changling Liu, Guang Huang, Jie Lan, Shulin Hao, Zhinian Li, Huichao Li, Aiying Guan, Airu Jiang, Ying Xu
  • Patent number: 8791158
    Abstract: The present invention includes methods for treating Meibomian gland dysfunctions. The invention also includes methods for improving tear lipid composition, for treating abnormal Meibomian gland secretion and for normalizing Meibomian gland secretions.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: July 29, 2014
    Assignee: GTX, Inc.
    Inventors: James T. Dalton, Jeetendra Eswaraka
  • Publication number: 20140206537
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: March 25, 2014
    Publication date: July 24, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: James E. Hunter, William C. Lo, Gerald B. Watson, Akshay Patny, Gary D. Gustafson, Dan Pernich, William K. Brewster, Debra L. Camper, Beth Lorsbach, Michael R. Loso, Thomas C. Sparks, Hemant Joshi, Adiraj Mandaleswaran, Ramadevi Sanam, Rambabu Gundla, Pravin S. Iyer
  • Patent number: 8759564
    Abstract: Novel amidoacetonitrile compounds and compositions containing the compounds are disclosed. The compounds have pesticidal properties and are suitable for controlling endoparasites on warm-blooded animals.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: June 24, 2014
    Assignee: Novartis AG
    Inventors: Thomas Goebel, Noëlle Gauvry, Heinz Sager
  • Publication number: 20140171314
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Publication number: 20140171308
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Publication number: 20140171309
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Publication number: 20140171503
    Abstract: Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.
    Type: Application
    Filed: June 15, 2012
    Publication date: June 19, 2014
    Applicants: Human Services
    Inventors: Jane B. Neckers, Yeong Sang Kim, Sunmin Lee, Vineet Kumar, Sanjay V. Malhotra
  • Publication number: 20140171312
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: William C. Lo, James E. Hunter, Gerald B. Watson, Akshay Patny, Pravin S. Iyer, Joshodeep Boruwa
  • Publication number: 20140155420
    Abstract: The invention provides small molecule inhibitors of EYA2 phosphatase activity and EYA2 binding to Six1. These inhibitors are proposed for use in methods of treating cancer in a subject, such as those involving Six1 and/or EYA2 disregulation. In some embodiments, the invention further provides for the administration of a second cancer therapy to the subject.
    Type: Application
    Filed: January 10, 2012
    Publication date: June 5, 2014
    Applicants: The Regents of the University of Colorado, a body corporate, Department of Health and Human Services
    Inventors: Rui Zhao, Heide L. Ford, Noel Southall, Erika Englund, Samarjit Patnaik, Marc Ferrer, Wei Zheng, Seameen Dehdashti, Juan Marugan
  • Patent number: 8741951
    Abstract: The present invention concerns compounds of general Formula (I): method of preparation and uses thereof.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: June 3, 2014
    Assignees: CNR—Consiglio Nazionale delle Ricerche, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) S.r.l.
    Inventors: Greta Varchi, Andrea Guerrini, Anna Tesei, Giovanni Brigliadori
  • Publication number: 20140134274
    Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.
    Type: Application
    Filed: October 24, 2013
    Publication date: May 15, 2014
    Applicant: University of Tennessee Research Foundation
    Inventors: Mitchell S. Steiner, Mary Ann Johnston, Michael L. Hancock, Jeffrey G. Hesselberg, James T. Dalton
  • Patent number: 8722930
    Abstract: A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors and are useful in the treatment of matriptase dependent conditions, particularly cancer.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: May 13, 2014
    Assignee: Orion Corporation
    Inventors: Rajeev Goswami, Anil Kumar Vuppala, Ramesh Veludandi, Ramesh Sistla, Chakshusmathi Ghadiyaram, Muralidhara Ramachandra
  • Publication number: 20140113012
    Abstract: The present invention provides compounds and compositions for the amelioration of arthritis and joint injuries by inducing mesenchymal stem cells into chondrocytes.
    Type: Application
    Filed: March 26, 2012
    Publication date: April 24, 2014
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Peter Schultz, Laure Bouchez
  • Publication number: 20140107088
    Abstract: Improved medical devices and methods are provided comprising an anabolic agent for healing an injury. These improved medical devices and methods can enhance healing in injuries from traumatic soft tissue injury, surgical injuries, burn, traumatic brain injuries, musculotendinous injuries, musculoskeletal conditions, bone injury or other injuries or maladies, which can be chronic or non-chronic in origin. In some embodiments, the medical device comprises a drug depot that releases the anabolic agent over at least 2 days to enhance healing of an injury.
    Type: Application
    Filed: November 20, 2013
    Publication date: April 17, 2014
    Applicant: Warsaw Orthopedic, Inc.
    Inventor: Jared T. Wilsey
  • Publication number: 20140086901
    Abstract: Compositions and methods for inhibiting the growth of solid tumors following radiation treatment are described. The compositions and methods target matrix metalloproteinases and bone marrow-derived cells expressing matrix metalloproteinases.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 27, 2014
    Inventors: John Martin Brown, G-one Ahn, Mitomu Kioi
  • Publication number: 20140080905
    Abstract: This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject.
    Type: Application
    Filed: July 29, 2013
    Publication date: March 20, 2014
    Applicant: GTx, Inc.
    Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
  • Patent number: 8669286
    Abstract: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: March 11, 2014
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Jeffrey D. Kearbey
  • Patent number: 8642799
    Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: February 4, 2014
    Assignee: Merck Canada Inc.
    Inventors: Elise Isabel, Christopher Mellon, Christian Beaulieu
  • Publication number: 20140018422
    Abstract: Disclosed herein are derivatives of tetracaine that, among other things, block cyclic nucleotide gated (CNG) channels and are useful in the treatment of diseases characterized by overactive CNG channels such as retinal degeneration diseases.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 16, 2014
    Inventors: Jeffrey Karpen, Sarah Kirk, Adriana Andrade, Michelle Schaffer, Kenneth Melich
  • Publication number: 20140005263
    Abstract: This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and/or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof.
    Type: Application
    Filed: May 21, 2013
    Publication date: January 2, 2014
    Applicant: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Donghua Yin, Yali He
  • Publication number: 20130324602
    Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.
    Type: Application
    Filed: April 23, 2013
    Publication date: December 5, 2013
    Inventors: James T. DALTON, Duane D. MILLER
  • Publication number: 20130296422
    Abstract: Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents —CHO, —C(?O)R5, —COOR5 (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.
    Type: Application
    Filed: November 1, 2011
    Publication date: November 7, 2013
    Applicant: ARIGEN PHARMACEUTICALS, INC.
    Inventors: Hiroyuki Saimoto, Kiyoshi Kita, Yoshisada Yabu, Masaichi Yamamoto
  • Publication number: 20130281444
    Abstract: The present invention provides a biphenyl benzamide-derived derivatives, which structure is selected from formula I or formula II: and the synthesis and the application thereof.
    Type: Application
    Filed: August 9, 2012
    Publication date: October 24, 2013
    Inventors: Deh-Ming CHANG, Hsu-Shan HUNAG, Chia-Chung LEE, Chun-Liang CHEN
  • Patent number: 8563606
    Abstract: The present invention relates to solid forms of (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.
    Type: Grant
    Filed: June 5, 2011
    Date of Patent: October 22, 2013
    Assignee: GTx, Inc.
    Inventors: James T. Dalton, David A. Dickason, Seoung-Soo Hong, Thomas G. Bird, Tai Ahn
  • Patent number: 8557282
    Abstract: The present invention relates to an extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: October 15, 2013
    Assignee: Lycored Bio Ltd.
    Inventor: Yoram Sela
  • Patent number: 8546448
    Abstract: A process for forming a solid electrolytic capacitor and an electrolytic capacitor formed by the process. The process includes: providing an anode wherein the anode comprises a porous body and an anode wire extending from the porous body; applying a thin polymer layer onto the dielectric, and forming a dielectric on the porous body to form an anodized anode; applying a first slurry to the anodized anode to form a blocking layer wherein the first slurry comprises a first conducting polymer with an median particle size of at least 0.05 ?m forming a layer of crosslinker on the blocking layer; and applying a layer of a second conducting polymer on the layer of crosslinker.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: October 1, 2013
    Assignee: Wellstat Therapeutics Corporation
    Inventors: Shalini Sharma, Reid W. von Borstel, Ramchandran Arudchandran, Rita O'Neil
  • Publication number: 20130244962
    Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.
    Type: Application
    Filed: April 11, 2013
    Publication date: September 19, 2013
    Applicant: Merck Frosst Canada Ltd.
    Inventors: Elise ISABEL, Christopher MELLON, Christian BEAULIEU